Cost Effectiveness Analysis of Sofosbuvir and Ledipasvir/Sofosbuvir in Hepatitis C Virus (HCV) Patients

Value in Health - United Kingdom
doi 10.1016/j.jval.2016.09.963
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Ledipasvir/Sofosbuvir Effectively Treats Hepatitis C Virus Infections in an Underserved Population

Digestive Diseases and Sciences
PhysiologyGastroenterology
2018English

Ledipasvir and Sofosbuvir for Recurrent Hepatitis C After Liver Transplantation

BioScience Trends
BiochemistryHealthMedicineGeneticsMolecular Biology
2016English

Ledipasvir and Sofosbuvir for HCV-infection in Patients Coinfected With HBV

Antiviral Therapy
Infectious DiseasesPharmacology
2016English

Ledipasvir / Sofosbuvir for the Treatment of Chronic Hepatitis C: A Cost-Effectiveness Analysis Across Different Genotype 1 Clinical Subgroups

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2015English

Secondary Occult Hepatitis C Virus Infection (HCV) in Chronic HCV Patients After Treatment With Sofosbuvir and Daclatasvir

International Journal of Current Microbiology and Applied Sciences
2018English

Sofosbuvir, Peg Interferon & Ribavirin for Retreatment of HCV Genotype 1b Following Sofosbuvir and Ledipasvir Failure

Hepatology
MedicineHepatology
2018English

Sofosbuvir (SOF) Suppresses Ledipasvir (LDV)-resistant Mutants During SOF/LDV Combination Therapy Against Genotype 1b Hepatitis C Virus (HCV)

Scientific Reports
Multidisciplinary
2017English

Sofosbuvir Plus Ledipasvir for Recurrent Hepatitis C in Liver Transplant Recipients

Liver Transplantation
HepatologyTransplantationSurgery
2017English

NS5A-P32 Deletion After Failure of Ledipasvir/Sofosbuvir in Hepatitis C Virus Genotype 1b Infection

Hepatology
MedicineHepatology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy